Health-related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.

Date publication

juin 2019

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Auteurs

Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie

Tous les auteurs :
Eberst G, Anota A, Scherpereel A, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Lena H, Rivière F, Monnet I, Gounant V, Janicot H, Gervais R, Locher C, Charton E, Morin F, Zalcman G, Westeel V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31175096

Résumé

The IFCT-GFPC-0701 MAPS Phase III trial highlighted significant improvement in overall survival from adding bevacizumab to the standard first-line chemotherapy regimen (cisplatin plus pemetrexed (PC)), in advanced malignant pleural mesothelioma (MPM). We present the results of health-related quality of life (HRQoL), a secondary endpoint of MAPS.

Référence

Clin. Cancer Res.. 2019 Jun 7;: